A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.
Sponsor: Nanjing Leads Biolabs Co.,Ltd
Listed as NCT05779163, this PHASE1/PHASE2 trial focuses on Advanced Malignant Tumors and remains actively recruiting participants. Sponsored by Nanjing Leads Biolabs Co.,Ltd, it has been updated 7 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jul 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing Leads Biolabs Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .